Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 2
1984 1
1985 1
1986 4
1987 2
1988 1
1989 1
1990 5
1991 4
1992 3
1993 1
1994 4
1995 6
1996 3
1997 1
1998 4
1999 9
2000 4
2001 5
2002 3
2004 3
2005 8
2006 5
2007 2
2009 2
2010 3
2011 2
2016 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

87 results
Results by year
Filters applied: . Clear all
Page 1
Pharmacological reversal of a pain phenotype in iPSC-derived sensory neurons and patients with inherited erythromelalgia.
Cao L, McDonnell A, Nitzsche A, Alexandrou A, Saintot PP, Loucif AJ, Brown AR, Young G, Mis M, Randall A, Waxman SG, Stanley P, Kirby S, Tarabar S, Gutteridge A, Butt R, McKernan RM, Whiting P, Ali Z, Bilsland J, Stevens EB. Cao L, et al. Among authors: mckernan rm. Sci Transl Med. 2016 Apr 20;8(335):335ra56. doi: 10.1126/scitranslmed.aad7653. Sci Transl Med. 2016. PMID: 27099175 Clinical Trial.
NMDA receptor pathways as drug targets.
Kemp JA, McKernan RM. Kemp JA, et al. Among authors: mckernan rm. Nat Neurosci. 2002 Nov;5 Suppl:1039-42. doi: 10.1038/nn936. Nat Neurosci. 2002. PMID: 12403981 Review.
gamma-Aminobutyric acid-A (GABA-A) receptor/ion channel complex.
Ragan CI, McKernan RM, Wafford K, Whiting PJ. Ragan CI, et al. Among authors: mckernan rm. Biochem Soc Trans. 1993 Aug;21 ( Pt 3)(3):622-6. doi: 10.1042/bst0210622. Biochem Soc Trans. 1993. PMID: 7693526 Review. No abstract available.
Preclinical and clinical pharmacology of TPA023B, a GABAA receptor α2/α3 subtype-selective partial agonist.
Atack JR, Hallett DJ, Tye S, Wafford KA, Ryan C, Sanabria-Bohórquez SM, Eng WS, Gibson RE, Burns HD, Dawson GR, Carling RW, Street LJ, Pike A, De Lepeleire I, Van Laere K, Bormans G, de Hoon JN, Van Hecken A, McKernan RM, Murphy MG, Hargreaves RJ. Atack JR, et al. Among authors: mckernan rm. J Psychopharmacol. 2011 Mar;25(3):329-44. doi: 10.1177/0269881109354928. Epub 2010 Feb 15. J Psychopharmacol. 2011. PMID: 20156926 Clinical Trial.
In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA receptor alpha5 subtype-selective inverse agonist.
Atack JR, Maubach KA, Wafford KA, O'Connor D, Rodrigues AD, Evans DC, Tattersall FD, Chambers MS, MacLeod AM, Eng WS, Ryan C, Hostetler E, Sanabria SM, Gibson RE, Krause S, Burns HD, Hargreaves RJ, Agrawal NG, McKernan RM, Murphy MG, Gingrich K, Dawson GR, Musson DG, Petty KJ. Atack JR, et al. Among authors: mckernan rm. J Pharmacol Exp Ther. 2009 Nov;331(2):470-84. doi: 10.1124/jpet.109.157636. Epub 2009 Aug 24. J Pharmacol Exp Ther. 2009. PMID: 19704033
87 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page